Testing two targeted drugs for KRAS G12C advanced cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of cancer called a KRAS G12C mutation (a genetic change that helps the cancer grow).
- Your cancer has spread to other parts of the body or cannot be cured with standard treatments.
- You are at least 18 years old and your daily activities are not limited much (able to care for yourself).
- Your liver, kidneys, and other organs are working well enough (checked by blood tests).
- You have not had major surgery in the last month, and you do not have active brain metastases or a gastrointestinal problem that affects how you absorb medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.